Home / Pharmaceuticals / Bacterial Vaginosis Drugs Market By Route of Administration (Oral Route : Metronidazole, Tinidazole, Clindamycin, Secnidazole; Topical Route : Metronidazole, Clindamycin, Normal pH Restoration Gels (VivaGel®, Canesbalance)) - Growth, Future Prospects & Competitive Analysis, 2017 – 2025

Bacterial Vaginosis Drugs Market By Route of Administration (Oral Route : Metronidazole, Tinidazole, Clindamycin, Secnidazole; Topical Route : Metronidazole, Clindamycin, Normal pH Restoration Gels (VivaGel®, Canesbalance)) - Growth, Future Prospects & Competitive Analysis, 2017 – 2025

Published: Nov 2017 | Report Code: 58853-11-17

The distribution pattern regarding occurrence of bacterial vaginosis is 18.8 % in celibate women, 25 % in pregnant women and 31.7 % in women who have ever been pregnant is considered as per the research findings of Center for Disease Control and Prevention. The risk factors associated with the disease etiology of bacterial vaginosis is pelvic inflammatory disease, preterm delivery of infants, urinary tract infection and sexually transmitted diseases (STD). The product pipeline in phase 3 for treatment of bacterial vaginosis are Metronidazole oral tablets 500mg | 1% SPL7013 Gel, GDC-229, Clindamycin 100mg and Ketoconazole 400mg and Association of metronidazole; nystatin and dexamethasone.

Oral route comprises of Metronidazole, Tinidazole, clindamycin and Secnidazole. The topical route includes Metronidazole, Clindamycin and normal pH restoration gels. The normal pH restoration gels is further sub segmented as Canesbalance and VivaGel®. Recent trends prevailing in the bacterial vaginosis drugs is understood by the inclusion of market size and forecast in the scope of the report.

Following geographical segmentation with their major countries have been included in the scope of the report:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of LATAM
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Market estimate and forecast for duration 2015-2025 has been reported for the major countries included in the regional segments to understand the country cross sectional market of the bacterial vaginosis drugs.

The competitive landscape and attractive investment proposition gives clear idea that the first line treatment drugs employed for the treatment of bacterial vaginosis and the product pipeline of key manufacturers engaged in the bacterial vaginosis treatment industry. Collaborative partnership between the key players to promote recently approved drugs are mentioned in the company profiles considered for bacterial vaginosis drugs market. The major players in global bacterial vaginosis drugs market are Sanofi Aventis, Inc., Bayer AG, Mylan N.V., Novartis AG, Pfizer, Inc., Perrigo Company Plc, Sun Pharmaceutical Industries Ltd., Abbott Laboratories, Inc., Starpharma Holdings Limited and Symbiomix Therapeutics.

Bacterial Vaginosis Drugs Market

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Bacterial Vaginosis Drugs Market Portraiture
2.1.1. Global Bacterial Vaginosis Drugs Market, by Route of Administration, 2016 (Value %)
2.1.2. Global Bacterial Vaginosis Drugs Market, by Geography, 2016 (Value %)

Chapter 3. Bacterial Vaginosis Drugs Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography
3.6. Top 3 Countries: Global Bacterial Vaginosis Drugs Market, 2015-2025 (US$ Mn)
3.7. Competitive Landscape: Global Bacterial Vaginosis Drugs Market, by Key Players, 2015-2025 (US$ Mn)

Chapter 4. Global Bacterial Vaginosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Bacterial Vaginosis Drugs Market, by Route of Administration, 2016
4.3. Oral Route
4.3.1. Metronidazole
4.3.2. Tinidazole
4.3.3. Clindamycin
4.3.4. Secnidazole
4.4. Topical Route
4.4.1. Metronidazole
4.4.2. Clindamycin
4.4.3. Normal pH Restoration Gels
4.4.3.1. VivaGel®
4.4.3.2. Canesbalance

Chapter 5. Global Bacterial Vaginosis Drugs Market, by Product Pipeline, Till- 2025 (US$ Mn)
5.1. Overview
5.2. Phase III Drug
5.2.1. GDC-229
5.2.2. Metronidazole oral tablets 500mg | 1% SPL7013 Gel
5.2.3. Clindamycin 100mg and Ketoconazole 400mg
5.2.4. Association of metronidazole; nystatin and dexamethasone
5.3. Tabular Representation of Phase II and Phase I Drugs

Chapter 6. Global Bacterial Vaginosis Drugs Market, by Geography, 2015 – 2025 (US$ Mn)
6.1. Overview
6.2. North America Bacterial Vaginosis Drugs Market Analysis, 2015 – 2025
6.2.1. North America Bacterial Vaginosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Mn)
6.2.2. North America Bacterial Vaginosis Drugs Market, by Country, 2015 – 2025 (US$ Mn)
6.2.2.1. U.S.
6.2.2.1.1. U.S. Bacterial Vaginosis Drugs Market, By Route of Administration, 2015-2025 (US$ Mn)
6.2.2.2. Canada
6.2.2.2.1. Canada Bacterial Vaginosis Drugs Market, By Route of Administration, 2015-2025 (US$ Mn)
6.3. Europe Bacterial Vaginosis Drugs Market Analysis, 2015 – 2025
6.3.1. Europe Bacterial Vaginosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Mn)
6.3.2. Europe Bacterial Vaginosis Drugs Market, by Country, 2015 – 2025 (US$ Mn)
6.3.2.1. U.K.
6.3.2.1.1. U.K. Bacterial Vaginosis Drugs Market, By Route of Administration, 2015-2025 (US$ Mn)
6.3.2.2. Germany
6.3.2.2.1. Germany Bacterial Vaginosis Drugs Market, By Route of Administration, 2015-2025 (US$ Mn)
6.3.2.3. Rest of Europe
6.3.2.3.1. Rest Of Europe Bacterial Vaginosis Drugs Market, by Route of Administration, 2015-2025 (US$ Mn)
6.4. Asia Pacific Bacterial Vaginosis Drugs Market Analysis, 2015 – 2025
6.4.1. Asia Pacific Bacterial Vaginosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Mn)
6.4.2. Asia Pacific Bacterial Vaginosis Drugs Market, by Country, 2015 – 2025 (US$ Mn)
6.4.2.1. Japan
6.4.2.1.1. Japan Bacterial Vaginosis Drugs Market, by Route of Administration, 2015-2025 (US$ Mn)
6.4.2.2. China
6.4.2.2.1. China Bacterial Vaginosis Drugs Market, by Route of Administration, 2015-2025 (US$ Mn)
6.4.2.3. India
6.4.2.3.1. India Bacterial Vaginosis Drugs Market, by Route of Administration, 2015-2025 (US$ Mn)
6.4.2.4. Rest of Asia Pacific
6.4.2.4.1. Rest Of Asia Pacific Bacterial Vaginosis Drugs Market, by Route of Administration, 2015-2025 (US$ Mn)
6.5. Latin America Bacterial Vaginosis Drugs Market Analysis, 2015 – 2025
6.5.1. Latin America Bacterial Vaginosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Mn)
6.5.2. Latin America Bacterial Vaginosis Drugs Market, by Country, 2015 – 2025 (US$ Mn)
6.5.2.1. Brazil
6.5.2.1.1. Brazil Bacterial Vaginosis Drugs Market, by Route of Administration, 2015-2025 (US$ Mn)
6.5.2.2. Mexico
6.5.2.2.1. Mexico Bacterial Vaginosis Drugs Market, by Route of Administration, 2015-2025 (US$ Mn)
6.5.2.3. Rest of Latin America
6.5.2.3.1. Rest Of Latin America Bacterial Vaginosis Drugs Market, by Route of Administration, 2015-2025 (US$ Mn)
6.6. Middle East & Africa Bacterial Vaginosis Drugs Market Analysis, 2015 – 2025
6.6.1. Middle East and Africa Bacterial Vaginosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Mn)
6.6.2. Middle East and Africa Bacterial Vaginosis Drugs Market, by Region, 2015 – 2025 (US$ Mn)
6.6.2.1. GCC
6.6.2.1.1. GCC Bacterial Vaginosis Drugs Market, by Route of Administration, 2015-2025 (US$ Mn)
6.6.2.2. Rest of Middle East and Africa
6.6.2.2.1. Rest Of Middle East and Africa Bacterial Vaginosis Drugs Market, by Route of Administration, 2015-2025 (US$ Mn)

Chapter 7. Company Profiles
7.1. Abbott Laboratories, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Bayer AG
7.3. Mylan N.V.
7.4. Novartis AG
7.5. Pfizer, Inc.
7.6. Perrigo Company Plc
7.7. Sun Pharmaceutical Industries Ltd.
7.8. Sanofi Aventis
7.9. Starpharma Holdings Limited
7.10. Symbiomix Therapeutics

List of Tables

TABLE 1 Global Bacterial Vaginosis Drugs Market Portraiture
TABLE 2 Global Bacterial Vaginosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 3 Global Bacterial Vaginosis Drugs Market, by Oral Route, 2015 – 2025 (US$ Mn)
TABLE 4 Global Bacterial Vaginosis Drugs Market, by Topical Route, 2015 – 2025 (US$ Mn)
TABLE 5 Global Bacterial Vaginosis Drugs Market, by Normal pH Restoration Gels, 2015 – 2025 (US$ Mn)
TABLE 6 Global Bacterial Vaginosis Drugs Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 7 North America Bacterial Vaginosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 8 North America Bacterial Vaginosis Drugs Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 9 U.S. Bacterial Vaginosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 10 Canada Bacterial Vaginosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 11 Europe Bacterial Vaginosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 12 Europe Bacterial Vaginosis Drugs Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 13 U.K. Bacterial Vaginosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 14 Germany Bacterial Vaginosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 15 Rest of Europe Bacterial Vaginosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 16 Asia Pacific Bacterial Vaginosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 17 Asia Pacific Bacterial Vaginosis Drugs Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 18 Japan Bacterial Vaginosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 19 China Bacterial Vaginosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 20 India Bacterial Vaginosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 21 Rest of Asia Pacific Bacterial Vaginosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 22 Latin America Bacterial Vaginosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 23 Latin America Bacterial Vaginosis Drugs Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 24 Brazil Bacterial Vaginosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 25 Mexico Bacterial Vaginosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 26 Rest of Latin America Bacterial Vaginosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 27 Middle East And Africa Bacterial Vaginosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 28 Middle East And Africa Bacterial Vaginosis Drugs Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 29 GCC Bacterial Vaginosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 30 Rest of Middle East and Africa Bacterial Vaginosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 31 Abbott Laboratories, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 32 Bayer AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 33 Mylan N.V.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 34 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 35 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 36 Perrigo Company Plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 37 Sun Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 38 Sanofi Aventis: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 39 Starpharma Holdings Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 40 Symbiomix Therapeutics: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)

List of Figures

FIG. 1 Bacterial Vaginosis Drugs: Market Segmentation
FIG. 2 Global Bacterial Vaginosis Drugs Market Share, by Route of Administration, 2016 (Value %)
FIG. 3 Global Bacterial Vaginosis Drugs Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography
FIG. 5 Market Competition Landscape, by Key Players, 2016
FIG. 6 Global Metronidazole Market for Bacterial Vaginosis Drugs, by Oral Route, 2015 – 2025 (US$ Mn)
FIG. 7 Global Tinidazole Market for Bacterial Vaginosis Drugs, by Oral Route 2015 – 2025 (US$ Mn)
FIG. 8 Global Clindamycin Market for Bacterial Vaginosis Drugs, by Oral Route, 2015 – 2025 (US$ Mn)
FIG. 9 Global Secnidazole Market for Bacterial Vaginosis Drugs, by Oral Route, 2015 – 2025 (US$ Mn)
FIG. 10 Global Metronidazole Market for Bacterial Vaginosis Drugs, by Topical Route, 2015 – 2025 (US$ Mn)
FIG. 11 Global Clindamycin Market for Bacterial Vaginosis Drugs, by Topical Route, 2015 – 2025 (US$ Mn)
FIG. 12 Global Vivagel pH Restoration Gels Market for Bacterial Vaginosis Drugs, 2015 – 2025 (US$ Mn)
FIG. 13 Global Canesbalance pH Restoration Gels Market for Bacterial Vaginosis Drugs, 2015 – 2025 (US$ Mn)

Based on route of administration, the bacterial vaginosis drugs market is categorized into:

  • Oral Route
    • Metronidazole
    • Tinidazole
    • Clindamycin
    • Secnidazole
  • Topical Route
    • Metronidazole
    • Clindamycin
    • Normal pH Restoration Gels
      • VivaGel®
      • Canesbalance

Bacterial Vaginosis Drugs Market

Bacterial vaginosis is the most common type of vaginal infection caused due to the pH imbalance in the vaginal environment which is triggered because of imbalance between good microflora Lactobacillus species with the bad microflora Gardnerella vaginalis. The clinical manifestation of bacterial vaginosis is asymptomatic in nature with the symptoms recurring with few days of earlier treatment with antibiotics. The treatment regimen is designed with drug formulations either oral or topical that are efficient in eliminating the colonization of Gardnerella vaginalis. Currently the antibiotics treatment is the preferred treatment regimen for bacterial vaginalis employing drugs such as metronidazole, clindamycin and Tinidazole. Broad spectrum antimicrobial activity e.g. secnidazole (Solosec) and immediate symptomatic relief makes antibiotic treatment the largest revenue grosser. Metronidazole is considered more beneficial than clindamycin for the treatment of bacterial vaginosis as it is safe during pregnancy and does not eliminate the colonization of good bacteria Lactobacillus species. Normal pH restoration gels e.g. Canesbalance (Bayer AG), VivaGel® (Starpharma Holdings)  will have an impressive growth in the near future as it address the key problem of microflora imbalance in vaginal environment and relatively has no side effects in comparison to the antibiotics. The prominent players in bacterial vaginosis drugs market are Abbott Laboratories, Inc., Bayer AG, Mylan N.V., Novartis AG, Pfizer, Inc., Perrigo Company Plc, Sun Pharmaceutical Industries Ltd., Sanofi Aventis, Starpharma Holdings Limited and Symbiomix Therapeutics.

For the purpose of this study, the global bacterial vaginosis drugs market is categorized into the following regional and country specific markets:

  • North America
    • United States
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Bacterial Vaginosis Drugs Market

Center for Disease Control and Prevention 2015 statistics has reported the prevalence of bacterial vaginosis in the North American women population to be around 84 % with no symptoms. The rising prevalence in the African American and Hispanic women has resulted the need for effective dosage regimen to give immediate relief. Domicile of key pharmaceutical industries engaged in the production and sale of antibiotics contributes to the dominance of North America in the bacterial vaginosis drugs market. European market is driven by rising prevalence of bacterial vaginosis due to increase in the lifetime number of sexual partners, recent influx of North African refugees with previous history of bacterial vaginosis has increased treatment burden to the European healthcare segment. Asia Pacific will enjoy a superlative growth in the bacterial vaginosis drugs market due to huge revenue generated by the generic antibiotic drugs market, poor socioeconomic conditions and lack of awareness regarding personal hygiene adds to the growth of Asia Pacific bacterial vaginosis drug market. Increasing disposable income and health awareness campaign regarding self hygiene by healthcare agencies such as World Health Organization and Red Cross will proliferate the bacterial vaginosis drugs market in Latin America and Middle East and Africa.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients